相关实验视频
Updated: Jan 18, 2026

Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
阻断血小板糖蛋白VI (GPVI) 作为一个有前途的抗血栓治疗
Ruofei Li1, Zhiwei Qiu2, Yimin Cui1
1Institute of Clinical Pharmacology, Peking University First Hospital, Beijing 100191, China; Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China.
糖蛋白VI (GPVI) 对于血小板激活和血栓生长至关重要. 向GPVI提供了一个有前途的抗血栓策略,具有最小的出血风险,正在研究glenzocimab和Revacept等药物.
科学领域:
- 生物化学 生物化学
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖蛋白VI (GPVI) 是血小板上的主要原受体.
- 在GPVI中介于原诱导的血小板激活和血栓形成.
- 此外,GPVI在炎症和癌症中也起作用.
研究的目的:
- 审查GPVI在血栓形成中的机制.
- 为了突出研究中的GPVI向药物,glenzocimab和Revacept.
- 总结目前的证据和基于GPVI的抗血栓治疗的未来方向.
主要方法:
- 关于血栓形成中的GPVI功能研究的文献综述.
- 对glenzocimab和Revacept的临床前和临床数据的分析.
- 检查GPVI在血液静止和出血表型中的作用.
主要成果:
- 抑制GPVI有效地减少了血栓形成.
- 抑制GPVI并没有显著损害血液静止.
- 缺乏GPVI的个体表现出轻度出血的表型.
- 格伦佐西马布和雷瓦塞普是有前途的抗血栓剂.
结论:
- 向GPVI是一个可行的抗血栓策略.
- 抑制GPVI提供了有效性和安全性之间的有利平衡.
- 针对GPVI向药物的进一步研究和临床试验是有必要的.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Peripheral Artery Disease III: Interprofessional Care

